Dr Jacob Adashek speaks to ecancer in an online interview for the virtual ESMO 2020 meeting about personalised molecularly matched therapies for carcinomas of unknown primary (CUP).
He explains that patients with CUP currently have a poor prognosis due to the rarity of the diagnosis, so the research aimed to take advantage of next-generation sequencing techniques to improve the outcomes of these patients.
Dr Adashek reports that their highly personalised approach resulted in improved outcomes and discusses the potential impact of these findings beyond the treatment of CUP.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.